TB VACCINES @ UNION WORLD CONFERENCE ON LUNG HEALTH
This page provides a list of sessions, presentations, and posters at the Union Conference related to TB vaccine R&D, as well as sessions that may be of interest to the TB vaccine R&D community. Registration is required for all Union Conference sessions.
All times are Brazil Standard Time
Click here for the full program and more information about the Union World Conference on Lung Health
Monday, 16 November
4th Annual New Tool Summit
9:00am - 6:00pm
Windsor Marapendi Hotel, Rio de Janeiro, Brazil
The event will be live-streamed
Hosted by the Working Groups of the Stop TB Partnership
Free of charge. Pre-registration required.
Tuesday, 17 November
10:00am - 1:00pm
Workshop: Talk the talk: An interactive workshop on tuberculosis messaging for introduction, uptake and impact
11:30am - 1:00pm
Oral Abstract Session: TB in the context of mobility, fragility and change
12:35 - 12:45pm: The impact and cost-effectiveness of a novel tuberculosis vaccine for new migrants to Canada
Oral Abstract Session: Stress testing AI for TB: Performance, calibration and adaptation
11:33 - 11:42am: A normative baseline for qXR tuberculosis scores to enable longitudinal CAD use in vaccine trials
Oral Abstract Session: Listening to affected community for effective TB care
11:35 - 11:42am: Listening, learning and leading: Barriers and enablers for adolescent and young adult TB vaccine update in the Cape Winelands, South Africa
1:15 - 2:50pm
TBScience E-Poster Session 1
1:50 - 1:55pm: Simple estimates of the short-term benefit of vaccination in IGRA- v IGRA+ individuals in high TB burden settings
2:00 - 2:05pm: Characteristics of asymptomatic TB for symptom-agnostic endpoint adolescent/adult TB vaccine licensure trials: A narrative review for the WHO technical advisory group
4:45 - 6:15pm
Oral Abstract Session: Feasibility and impact of prevention strategies
5:36 - 5:44pm: How could a new TB vaccine help Brazil belatedly achieve the End TB Targets?
5:44 - 5:52pm: Projected health, budget, and cost-effectiveness impacts of stakeholder-informed tuberculosis vaccine strategies in South Africa: A modelling analysis
Wednesday, 18 November
10:00 - 10:45am
Community Connect: Ready, set, go: A multi-country dialogue on community readiness for new TB vaccines
12:00 - 1:00PM
E-Posters: Vaccination and other population approaches to TB prevention
TBScience E-Poster Session 4
12:15 - 12:20: Symptom-agnostic screening to increase endpoint accrual in TB vaccine efficacy trials
E-Posters: Nourish to flourish: Nutrition in TB care
12:30 - 12:36: The potential effect of varying vaccine efficacy by nutritional status on population-level impact of introducing new TB vaccines in India
2:15 - 3:45pm
Symposium: Equitable innovation: Championing the human right to science in TB research and development
3:28 - 4:30pm
TBScience Session: Potential impact of heterogeneity on transmission, treatment outcomes and vaccine efficacy
4:00 - 5:30pm
Symposium: New TB vaccines on the horizon: Planning for equitable and timely introduction in high burden countries
17:40 - 19:10
TBScience Session: Identification of correlates of risk (CoR) and protection (CoP) following vaccination with M72/AS01E
5:45 - 7:15pm
Satellite Session: Delivering future TB vaccines: Modelling impact, enabling access and country readiness
Satellite Session: Towards 2030: Introducing and integrating next-generation innovations for resilient, people-centered tuberculosis care
6:24 - 6:41pm: People-powered TB care: Advancing meaningful community leadership in introduction and scale of emerging TB innvocations
6:41 - 6:58pm: What we can learn from malaria and HBV vaccines to inform pathways for scaled access to new TB vaccine candidates.
Thursday, 19 November
9:15 - 10:45am
Spotlight Session: Finding TB before it spreads: Population wide active case finding for TB elimination
10:11 - 10:21am - From finding TB to preventing TB: how population wide active case finding could align with prevention and future vaccines.
Oral Abstract Session: Alchemy: Dose determination, safety and adverse effects in preclinical and clinical TB trials
10:14 - 10:22am - Safety and immunogenicity of two investigational mRNA-based vaccine candidates against tuberculosis in IGRA-negative and -positive healthy adults in South Africa
Oral Abstract Session: LATAM Mapping the TB journey: Prevention, screening, diagnostic, treatment and long term care
9:18 - 9:26am: Modelling the potential impact of vaccinating children, adolescents, or young adults with a new tuberculosis vaccine in Brazil
11:00am - 12:00pm
Plenary Session: The vaccine lifecycle: Advancing translational science, equity and community confidence
12:00 - 1:00pm
TBScience E-Poster Session 7
12:30 - 12:35pm - Safety of the M72/AS01 tuberculosis vaccine in people living HIV: A systematic review and meta analysis
E-Posters: LATAM Quality TB prevention and care
12:45 - 12:50: Preparing for new TB vaccines in Brazil: Insights from a stakeholder survey
1:10 - 2:10pm
E-Posters: Prioritising youth interventions to end TB
1:20 - 1:25pm: Projected impact of new TB vaccination under various stakeholder informed adolescent delivery scenarios in Indonesia
4:35 - 5:30pm
TBScience Session: Innovations in diagnostics and vaccines - oral abstracts
4:36 - 4:43pm - Potential to improve tuberculosis vaccine efficiency with symptom-agnostic screening: A mathematical modelling study.
5:11 - 5:18pm - Next-generation inhaled Ad5-vectored TB vaccine: Preclinical efficacy and first-in-human translation
Friday, 20 November
12:15 - 1:45pm
Satellite Session: Tackling tuberculosis today and for the future: From pipeline innovation to global collaboration
12:20 - 12:37pm - Preparing for TB M72 vaccine implementation
3:00 - 3:45pm
Community Connect Session: From science to access: Mobilising community for new TB vaccines
4:00 - 5:30pm
Symposium: Scenario Planning for Novel Tuberculosis Vaccine Policy Decisions
4:35 - 5:40pm
TBScience Sessions: Translational innovations in TB prevention, treatment, and diagnostics - oral abstracts
4:36 - 4:43pm - Kinetics and durability of immune responses by two investigational mRNA-based vaccine candidates against tuberculosis in Mycobacterium tuberculosis-naive and -exposed populations.
Is there other TB vaccine-related content at the Union Conference? Contact us to let us know so we can add it to this list!